Hormonal
Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces clinically significant, dose-dependent reductions in body weight, HbA1c, systolic blood pressure, and atherogenic lipids (LDL, VLDL, triglycerides) with high consistency across trials.
Orforglipron is an oral medication that helps reduce weight, blood sugar, blood pressure, and bad cholesterol. It works by mimicking a gut hormone (GLP-1). You take one pill a day. It can cause stomach issues like nausea, but doctors can help manage this by starting with a low dose and increasing it slowly. It is designed for people with obesity or type 2 diabetes who want to avoid injections.
orforglipron produced dose-dependent, clinically meaningful improvements in major modifiable cardiovascular risk factor compared with placebo: body weight − 6.08%... HbA1c − 0.85%... systolic blood pressure − 4.32 mmHg... LDL-cholesterol − 4.14%... triglycerides − 10.90%... VLDL-cholesterol − 10.81%... and HDL-cholesterol + 3.31%.
Why this rating
Meta-analysis of 4 large Phase 2/3 RCTs with low heterogeneity for key lipid/BP outcomes.
Source
Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review
Adir Alper et al. · Cardiovascular Diabetology – Endocrinology Reports · 2026
DOI 10.1186/s40842-025-00270-4
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →